ERBB2 and breast cancer: The internalization and nuclear transport of trastuzumab-PEG-[195Pt]Pt-AuNPs suggests that these agents incorporating the AE-emitters 193Pt or 195mPt may be cytotoxic to HER2-positive BC cells and provide useful radiation nanomedicines for treating BC overexpressing HER2, but further studies are needed to explore this approach.